Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
Regeneron Pharmaceuticals has five pipeline candidates in late-stage development in Japan, global commercial chief Marion McCourt said in a Tokyo interview on December 10. This includes the BCMA/CD3 bispecific antibody linvoseltamab — which is slated for domestic filing sometime in…
To read the full story
Related Article
- Regeneron Files Libtayo for Squamous Cell Carcinoma in Japan
December 12, 2025
- Regeneron Bolsters Japan Oncology Team as Libtayo Gains Ground
October 3, 2025
- Regeneron to Upsize Japan Workforce after Libtayo Transfer
February 13, 2025
- Regeneron to Hire 73 Rhinology Sales Reps to Back Dupixent Label Expansion
August 28, 2024
- Regeneron Takes Over Japan Marketing Authorization for Libtayo from Sanofi
June 4, 2024
- Regeneron Set for Commercial Expansion in Japan, Eyes Dupixent Ramp-Up
May 1, 2024
- Regeneron to Make Japan Debut with Dupixent Copromotion
September 27, 2023
BUSINESS
- Santen Eyes Pterygium Drug as Key Pipeline Asset, 4 Million Potential Patients in Japan
March 23, 2026
- Chugai Files Device Component of Ranibizumab Eye Implant in Japan
March 23, 2026
- Shionogi’s Zurzuvae, Kissei’s Yselty Now Available in Japan
March 23, 2026
- Boehringer Files Hernexeos for First-Line NSCLC Use in Japan
March 23, 2026
- Novo Japan Logs 5.4% Growth in 2025, Sees Wegovy Powering Push for Double-Digit Goal
March 23, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…